VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-1 1 with a maximal effect observed at 0.5mg to 1.0 mg QD. For more information on the Phase 1a trial results, please ...
RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double ...